Rifaximin drug interactions: Difference between revisions
(Created page with "__NOTOC__ {{Rifaximin}} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = XIFAXAN (RIFAXIMIN) TABLET [SALIX PHARMACEUTI...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Drug Interactions== | |||
In vitro studies have shown that rifaximin did not inhibit cytochrome P450 isoenzymes 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1 and CYP3A4 at concentrations ranging from 2 to 200 ng/mL [see Clinical Pharmacology ]. Rifaximin is not expected to inhibit these enzymes in clinical use. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = XIFAXAN (RIFAXIMIN) TABLET [SALIX PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5e8e2fd-7087-4b78-9181-cc259c0be2f1 | publisher = | date = | accessdate = }}</ref> | An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology]. However, in patients with normal liver function, rifaximin at the recommended dosing regimen is not expected to induce CYP3A4. It is unknown whether rifaximin can have a significant effect on the pharmacokinetics of concomitant CYP3A4 substrates in patients with reduced liver function who have elevated rifaximin concentrations. | ||
An in vitro study suggested that rifaximin is a substrate of P-glycoprotein. It is unknown whether concomitant drugs that inhibit P-glycoprotein can increase the systemic exposure of rifaximin [see Clinical Pharmacology ]. <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = XIFAXAN (RIFAXIMIN) TABLET [SALIX PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5e8e2fd-7087-4b78-9181-cc259c0be2f1 | publisher = | date = | accessdate = }}</ref> | |||
Latest revision as of 21:35, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Drug Interactions
In vitro studies have shown that rifaximin did not inhibit cytochrome P450 isoenzymes 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1 and CYP3A4 at concentrations ranging from 2 to 200 ng/mL [see Clinical Pharmacology ]. Rifaximin is not expected to inhibit these enzymes in clinical use.
An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology]. However, in patients with normal liver function, rifaximin at the recommended dosing regimen is not expected to induce CYP3A4. It is unknown whether rifaximin can have a significant effect on the pharmacokinetics of concomitant CYP3A4 substrates in patients with reduced liver function who have elevated rifaximin concentrations.
An in vitro study suggested that rifaximin is a substrate of P-glycoprotein. It is unknown whether concomitant drugs that inhibit P-glycoprotein can increase the systemic exposure of rifaximin [see Clinical Pharmacology ]. [1]
References
Adapted from the FDA Package Insert.